21 completed, 8 recruiting, 5 terminated, 4 unknown. 42 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 42 | Completed 21, Recruiting 8, Terminated 5, Unknown 4, Active not recruiting 3, Not yet recruiting 1 |
| Phase 2 | 7 | Completed 3, Recruiting 2, Terminated 1, Unknown 1 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-11-13 |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement Avacopan, Placebo - ANCA-Associated Vasculitis (AAV) | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 130 | 2026-03-01 | 2026-01-28 |
| Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Cyclophosphamide, Standard of Care (SOC), Prednisone - Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA) | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 36 | 2025-11-10 | 2026-01-30 |
| BDB-001 Phase III Trial in ANCA-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Rituximab - ANCA Associated Vasculitis (AAV) | Phase 3 | Recruiting | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 300 | 2025-11-10 | 2026-08-13 |
| Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Rituximab, Tocilizumab, Tofacitinib - Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 42 | 2025-06-06 | 2026-04-03 |
| A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases Benralizumab - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) | Phase 3 | Recruiting | AstraZeneca | 14 | 2025-04-17 | 2026-10-28 |
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
| A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial Pioglitazone (ACTOS®), Placebo of Pioglitazone - ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 126 | 2023-10-24 | 2026-07-01 |
| Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Depemokimab, Mepolizumab, Placebo matching mepolizumab - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Active not recruiting | GlaxoSmithKline | 163 | 2022-07-14 | 2026-07-08 |
| Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Mepolizumab, cyclophosphamide/azathioprine, Placebo - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 102 | 2022-05-30 | 2026-10-01 |
| COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases COVID-19 vaccine - Rheumatoid Arthritis, Autoimmune Rheumatologic Disease | Phase 2 / Phase 3 | Unknown | Paul R Fortin | 287 | 2022-03-09 | 2023-01-17 |
| Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Rituximab, placebo - Microscopic Polyangiitis (MPA) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 8 | 2020-10-24 | 2026-05-06 |
| Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. Benralizumab, Mepolizumab, Placebo to Mepolizumab - Eosinophilic Granulomatous Vasculitis | Phase 3 | Active not recruiting | AstraZeneca | 140 | 2019-10-29 | 2026-11-09 |
| Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis Rituximab, endoxan, Methylprednisolone - ANCA Associated Vasculitis | Phase 3 | Unknown | Leiden University Medical Center | 100 | 2019-05-03 | 2023-12-14 |
| Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Rituximab, Azathioprine, Placebo-rituximab - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 98 | 2018-03-07 | 2025-11-20 |
| Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Discontinuation (or not initiation) of Immunosuppressive Therapy, Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl® - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease | Phase 3 | Active not recruiting | Centre Hospitalier Departemental Vendee | 136 | 2018-02-02 | 2026-03-20 |
| A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Avacopan, Prednisone, Cyclophosphamide - ANCA-Associated Vasculitis | Phase 3 | Completed | Amgen | 331 | 2017-03-15 | 2025-03-24 |
| Rituximab in Eosinophilic Granulomatosis With Polyangiitis Rituximab, Placebo-rituximab, Cyclophosphamide - Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 107 | 2016-12-05 | 2026-01-15 |
| Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Abatacept, placebo - Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis | Phase 3 | Completed | University of South Florida | 65 | 2015-04-25 | 2024-07-29 |
Showing 20 of 42. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (21) · Granulomatosis with Polyangiitis (20) · Microscopic Polyangiitis (15) · Vasculitis (15) · Churg-Strauss Syndrome (11) · Arthritis, Rheumatoid (2) · Lung Diseases (2) · Lupus Erythematosus, Systemic (2) · Recurrence (2) · Respiratory Tract Diseases (2) · Vascular Diseases (2) · Asthma (1) · Autoimmune Diseases (1) · Cardiovascular Diseases (1)
Immune System Diseases (42) · Skin and Connective Tissue Diseases (42) · Autoimmune Diseases (41) · Cardiovascular Diseases (41) · Skin Diseases (41) · Skin Diseases, Vascular (40) · Vascular Diseases (40) · Vasculitis (27) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (19) · Lung Diseases (19) · Lung Diseases, Interstitial (19) · Respiratory Tract Diseases (19) · Brain Diseases (16) · Central Nervous System Diseases (16)
Rituximab (13) · Azathioprine (12) · Cyclophosphamide (10) · Prednisone (8) · mepolizumab (6) · Glucocorticoids (4) · Methylprednisolone (3) · avacopan (3) · benralizumab (3) · Adrenal Cortex Hormones (2) · Methotrexate (2) · Mycophenolic Acid (2) · Plasma Exchange (2) · Prednisolone (2) · Abatacept (1)
Assistance Publique - Hôpitaux de Paris (12) · AstraZeneca (3) · Cambridge University Hospitals NHS Foundation Trust (3) · GlaxoSmithKline (3) · University of Pennsylvania (2) · University of South Florida (2) · Amgen (1) · Centre Hospitalier Departemental Vendee (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Hospices Civils de Lyon (1) · Human Genome Sciences Inc., a GSK Company (1) · Joseph Mccune (1) · Leiden University Medical Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
France (24) · United States (17) · Canada (14) · United Kingdom (12) · Italy (8) · Netherlands (8) · Belgium (7) · Germany (7) · Japan (7) · Czechia (5) · Sweden (5) · Australia (4) · Ireland (4) · Israel (4) · Poland (4)
Loic Guillevin, MD, PhD (3) · Peter A Merkel, MD, MPH (3) · David Jayne, MD (2) · Jeffrey P Krischer, PhD (2) · John H. Stone, MD, MPH (2) · Alexandre Karras (1) · Benjamin Terrier (1) · Benjamin Terrier, MD, PhD (1) · Carol A Langford, MD, MHS (1) · Caroline OS Savage (1) · Coen Stegeman, MD PhD (1) · David Jayne (1) · David Massicotte-Azarniouch, MD, MSc (1)
PMID 28592297, PMID 39425055, PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16378799, PMID 16646004, PMID 16914703, PMID 17407214, PMID 17557758, PMID 18163506, PMID 19109574, PMID 19451574, PMID 20647199, PMID 21060104, PMID 22127969, PMID 22975753, PMID 23615499, PMID 23754238, PMID 23902481, PMID 25047592, PMID 25372085, PMID 25776953, PMID 26387933, PMID 26621483, PMID 27049404, PMID 27696762, PMID 28246067, PMID 28270229, PMID 28514601, PMID 28678392, PMID 29695500, PMID 29724729, PMID 30666823, PMID 31056661, PMID 31216123, PMID 32053298, PMID 32088663, PMID 32479166, PMID 33164993, PMID 33367837, PMID 33596356, PMID 34618687, PMID 35167187, PMID 36130755, PMID 36155131, PMID 36958796, PMID 37134130, PMID 37903568
2023 (3), 2016 (2), R01HL115041 (2), U54AR057319 (2), 2009 (1), 2014 (1), 2018 (1), 2019 (1), R01HD066139 (1)